Can a Dual-Action antibody outsmart advanced solid tumors?

NCT ID NCT07744243

Not yet recruiting Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Aug 04, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This phase 1 trial is evaluating an investigational drug called SI-B036, a bispecific antibody designed to target cancer cells in a unique way. The study will enroll about 30 adults with locally advanced or metastatic urological tumors or other solid tumors. The main goals are to assess the safety, tolerability, and appropriate dosing of SI-B036, while also looking for early signs of its anti-tumor activity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SI-B036 bispecific antibody injection
What this could lead to: If successful, this could lead to a new treatment option for advanced urological and other solid tumors, potentially slowing disease progression.
What could go wrong: This is an early-phase trial with a small number of participants, so the drug may not be effective or may cause significant side effects. The results are preliminary and require further study.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

benign urinary system neoplasm cancer malignant urinary system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID CANCER UROLOGICAL CANCER

Contacts and locations

Locations

Peking University First Hospital

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.